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Abstract 
Background-and-Purpose: we assessed whether the presence, number and distribution 
of cerebral microbleeds (CMBs) on pre-IV thrombolysis acute ischaemic stroke MRI scans 
are associated with an increased risk of intracerebral haemorrhage (ICH), or poor functional 
outcome. 
Methods: We performed an individual patient data meta-analysis including prospective and 
retrospective studies of acute ischaemic stroke treated with IV tPA. Using multilevel mixed-
effects logistic regression, we investigated associations of pre-treatment CMB presence, 
burden (1, 2-4, ≥5 and >10) and presumed aetiology (cerebral amyloid angiopathy (CAA) 
defined as strictly lobar CMBs; and non-CAA) with symptomatic ICH (sICH), parenchymal 
haematoma (within (PH) and remote from the ischaemic area (PHr)); and poor 3-6 month 
functional outcome (modified Rankin Score (mRS) >2).  
Results: In 1973 patients from eight centres, the crude prevalence of CMBs was 526/1973 
(26.7%). 77/1973 (3.9%) patients suffered sICH; 210/1806 (11.6%) PH, and 56/1720 (3.3%) 
PHr. In adjusted analyses, patients with CMBs (compared to those without CMBs) had 
increased risk of PH (OR: 1.50; 95%CI: 1.09-2.07; p=0.013), and PHr (OR: 3.04; 95%CI: 
1.73-5.35; p<0.001) but not sICH. Both CAA and non-CAA patterns of CMBs were 
associated with PH and PHr. Increasing CMB burden category was associated with the risk 
of sICH (p=0.014), PH (p=0.013) and PHr (p<0.00001). Five or more, and >10 CMBs 
predicted poor 3-6 month outcome (OR:1.85(95% CI 1.10-3.12, p=0.020; and OR:3.99 
(95%CI: 1.55-10.22, p=0.004, respectively). 
Conclusions: Increasing CMB burden is associated with increased risks of ICH (including 
PHr) and poor 3-6 month functional outcome after intravenous thrombolysis for acute 
ischaemic stroke.  
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Introduction 
Intravenous thrombolysis with recombinant tissue plasminogen activator (IV tPA) has benefit 
in acute ischaemic stroke,1 but some patients are harmed by early symptomatic intracerebral 
haemorrhage (sICH), associated with poor outcome.2, 3 Inceasing age, stroke severity, blood 
pressure, early ischaemic change and hyperglycaemia are associated with increased sICH 
risk,2-4 but have not led to robust prediction scores.5 
Patterns of ICH after thrombolysis include haemorrhage within the infarct and remote 
bleeding.4 Cerebral microbleeds (CMBs), detected on blood-sensitive MRI, are a marker of 
haemorrhage-prone small vessel pathology,6 which might contribute, particularly to remote 
ICH. In a recent meta-analysis, pre-treatment CMBs increased the odds of sICH (pooled 
OR: 2.87; 95% CI: 1.76–4.69; p<0.0001),7 but could not investigate CMB burden, 
distribution, or key confounders.7 
We performed a large-scale pooled individual patient data meta-analysis of quality 
observational studies to test the following hypotheses: (1) there is a relationship between 
increasing CMB burden and ICH risk;8, 9 (2) strictly lobar CMBs (reflecting possible or 
probable cerebral amyloid angiopathy [CAA]) and mixed or strictly deep CMBs (likely 
associated with hypertensive arteriopathy) have different effects on ICH risk; (3) CMBs are 
associated more strongly with the risk of remote ICH than other ICH types;10 and (4) CMBs 
are associated with worse functional outcome. 
Methods 
Study design and inclusion criteria 
We identified prospective or retrospective studies which assessed pre-treatment MRI-
defined CMBs, ICH, and 3-6 month functional outcome after acute ischaemic stroke, treated 
solely with IV tPA, from a systematic review prepared according to PRISMA11 7 (updated 1st 
August 2015). We searched:  PubMed for “micro(-)bleed*”, or “micro(-)h(a)emorrhag*, or 
“gradient-echo”, or “susceptibility-weighted” in association with “thromboly*” or “tPA”, or 
“tissue plasminogen activator”;7 reference lists; and authors’ own files. Supplementary Figure 
1 shows a flow diagram. 
We collected anonymised individual patient detailed clinical data, and CMB counts in 
lobar, deep and infratentorial regions according to standardised definitions6, 12, 13 using 
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standardised report forms. A pre-specified protocol was circulated to collaborators, but not 
published. 
Outcomes 
We defined ICH according to European Cooperative Acute Stroke Study II (ECASS-2)14, 15 
including: haemorrhagic infarction (HI); parenchymal haemorrhage (PH); and symptomatic 
ICH16 (sICH, acute intracerebral blood and associated increase in NIHSS ≥4 points, except 
one study17 which used the definition in the PROACT-II trial).18 Remote parenchymal 
haemorrhage (PHr) was defined as ICH remote from the symptomatic ischaemic area.10 We 
defined poor outcome at 3-6 months as mRS>2.  
Assessing the risk of bias 
We critically appraised all studies against quality indicators,9, 19, 20 with reference to the 
STROBE statement and ideal characteristics.21 7 
Statistical analysis 
Using one-stage meta-analysis22 and mixed-effects logistic regression (modelling different 
centres as random effects), we investigated the associations of CMBs presence, burden (pre-
specified as 1, 2-4, 5-10 and >10 CMBs categories, clinically relevant for ICH risk9), number 
(log-transformed for normality, +1 to account for zero cells), and location, with ICH 
subtypes (sICH, PH, PHr) and functional outcome, using no CMBs as a reference group. The 
overall p-value for CMBs as a categorical predictor was obtained and reported for each ICH 
outcome. CMB distribution was classified as “CAA-related” (strictly lobar, including possible 
and probable CAA), and “non-CAA-related” (mixed or strictly deep). We adjusted all 
models for sICH risk factors available in all patients (treatment delay, age, and baseline 
NIHSS, as continuous variables, log transformed as appropriate);1 and for MRI sequence 
characteristics (T2*-GRE/SWI and field strength) which influence CMBs detection.23 In post-
hoc sensitivity analyses, we also adjusted for sex, hypertension, atrial fibrillation, and 
admission systolic and diastolic blood pressures. We used a similar approach to investigate 
CMBs as a predictor of poor 3-6 month functional outcome (mRS>2). We used Stata 13 
(StataCorp LP, Texas) and prepared this report with reference to the Preferred Reporting 
Items for Systematic Review and Meta-Analyses of individual participant data (PRISMA-IPD)24 
(supplemental Table I) and the Cochrane Handbook. 
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Results 
We obtained data for 2048 participants from eight centres 8, 17, 25-28. Individual patient data 
was not available from the BRASIL multicenter study (n=570)29, 30 with similar quality and 
characteristics to studies included.7 We excluded one study of mainly IV and intra-arterial 
treatment.31 We included 1973 (96%) participants in ICH analyses and 1894 (93%) in 
functional outcome analysis. One study (n=253) did not provide PHr32 or CMB distribution 
data;32 another (n=167)17 did not provide HT/PH data, resulting in different numbers in 
outcome analyses (Supplemental Figure I and Supplemental Table 1I). Details of the cohorts 
included are provided in Tables 1 and 2. 
Crude prevalence rates were as follows: any CMBs 526/1973 (26.7%); sICH 77/1973 
(3.9%); PH 210/1806 (11.6%); PHr 56/1720 (3.3%); and HI 338/1806 (18.7%; symptomatic in 
9 cases). In adjusted analyses (Table 3), patients with any CMBs (compared to those without 
CMBs) had a higher risk of PH (OR: 1.50; 95%CI: 1.09-2.07), and PHr (OR: 3.04; 95%CI: 
1.73-5.35), but not sICH (OR: 1.42; 95%CI: 0.86-2.35;) or HI. In the overall full ‘categorical’ 
model, increasing CMBs burden (1, 2-4, 5-10, and >10) was associated with sICH, PH and 
PHr (overall p-values: 0.014, 0.013 and <0.00001 respectively); effect estimates for different 
CMBs burden categories and log CMBs number are shown in Table 3.  
CAA-related CMB increasing burden category was associated with the risk of PHr 
(overall p=0.001), and marginally with PH (overall p=0.06) (Table 4). Increased burden 
category of non-CAA CMBs was associated with the risk of PH (overall p=0.006) and PHr 
(overall p=0.003); effect estimates of different CMBs distribution and burden categories and 
log CMBs number are shown in Table 4.  
Results were similar in sensitivity analyses also adjusted for sex, hypertension, atrial 
fibrillation and admission systolic and diastolic blood pressure. The main fully adjusted model 
for CMB burden is summarised in Supplemental Table III. 
746 of 1894 (39%; 95%CI: 37-42%) patients had poor outcome (mRS>2) at 3–6 months, 
which was associated with ≥5 and >10 CMBs (OR:1.85 (95% CI 1.10-3.12, p=0.020; and 
OR:3.99 (95%CI: 1.55-10.22, p=0.004, respectively). Non-CAA-related CMBs (but not CAA-
related CMBs) predicted poor outcome; CMBs were not associated with 3-6 month 
mortality (Table 5). 
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Discussion 
Our individual patient data meta-analysis shows that pre-thrombolysis CMBs are 
independently associated with increased risk of ICH and poor functional outcome after 
acute ischaemic stroke. CMBs might be most strongly associated with PHr than PH, but the 
odds ratio 95% confidence intervals overlapped. Although CMB presence was not related to 
an increased risk of sICH as suggested by previous meta-analyses7 (perhaps due to the 
inclusion of slightly different cohorts and model adjustments),25, 30 increasing CMB category 
burden was associated with increased risk of sICH, PH and PHr. More than 5 CMBs was 
associated with a doubling, and >10 CMBs with a four-fold increase in the odds of poor 
functional outcome. 
Most ICHs after thrombolysis occur within the acute ischemic area, but a minority 
occur remotely.4, 10 While ICH within the ischaemic area results from reperfusion and 
vascular injury in the territory of an occluded vessel, PHr is plausibly due to widespread pre-
existing bleeding-prone cerebral small vessel diseases.4, 10, 33 We observed a strong 
association between PHr and CMBs, supporting this hypothesis, consistent with an 
association between ‘previous vascular pathology’ and PHr.10 CMBs develop rapidly in acute 
ischemic stroke, a process which could be aggravated by thrombolysis.34 Increasing CAA-
related CMBs burden was associated with PHr (p=0.001) but only marginally with PH 
(p=0.06) while non-CAA-related CMB burden was linked to PH and PHr. Five or more 
CAA-related CMBs had the highest PHr risk, but with very wide confidence intervals.   
Previous neuropathological data directly link CAA to thrombolysis-related ICH,33 as does an 
amyloid-β PET study.35 Although the effect sizes in our study suggest a possible stronger 
relationship for CMBs with PHr, we did not definitively demonstrate this statistically, so this 
should be investigated further in future studies. 
Multiple CMBs (≥5 or >10) were associated with increased risk of poor outcome, 
though only 35/20143 (2%) of patients had >10 CMBs; some clinicians might already exclude 
similar patients from IV tPA. Worse functional outcome with multiple CMBs might be 
explained by vulnerability to acute ischaemia (through impaired microcirculation or 
collateral function), or poorer functional recovery due to impaired cerebral connectivity. 
Our study has strengths: large-scale individual patient data gave statistical power to test 
hypotheses about CMB burden and distribution,7, 9, 20 using standardized classification and 
adjustment for confounding factors.  
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We acknowledge limitations. Heterogeneous study characteristics might still partly 
account for some reported associations: MRI parameters could affect CMBs category; not 
all patients undergo MRI; and patient characteristics, treatment, and follow-up protocols 
varied.7 We could not include some potential confounders, e.g. infarct volume, acute 
thrombus, clinical syndrome, concomitant treatments (antiplatelets, anticoagulants, statins), 
early ischaemic changes, hyperglycaemia, leukoaraiosis, or pre-stroke mRS.  
We confirm that CMBs are associated with an increased risk of ICH after IV 
thrombolysis. Although some CMB subgroups had higher risk of poor functional outcome, 
our data do not establish the risk vs. benefit ratio of IV tPA in relation to CMBs so 
treatment should not be witheld from otherwise eligible patients solely because of CMBs. 
However, clinicians might consider many CMBs a risk factor for ICH or poor outcome, to 
inform clinical decisions and prognosis; randomized trials of pre-treatment CMB evaluation 
versus standard imaging might be justified. 
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Tables 
Table 1. Baseline characteristics of patients  
 
Turc et al.25 
(Lille cohort) 
Turc et al.25 
(Paris cohort) 
Kakuda et al27 Yan et al 26 
Dannenberg et 
al 8 
Gratz et al 17 Moriya et al 28 Kimura et al 32 TOTAL 
Patient number (% men) 375 (42%) 342 (56%) 70 (57%) 433 (66%) 326 (51%) 167 (64%) 71 (70%) 257 (56%) 2048 (56%) 
Age (yrs) median (IQR) 77 (63 to 85) 70 (58 to 80) 75 (66 to 82) 67 (58 to 75) 76 (68 to 84)  71 (63 to 79) 75 (66 to 81) 77 (69 to 83) 73 (62 to 81) 
Treatment delay (hours) median (IQR) 2.5 (2 to 3.2) 2.7 (1.2 to 2.1) 5.4 (5.2 to 5.8) 3.6 (2.7 to 4.5) 2.3 (1.8 to 3.4) 3.2 (2.6 to 3.8) 2.5 (2.1 to 2.7) 2.5 (2.1 to 2.9) 2.8 (2.1 to 3.7) 
Stroke severity (NIHSS) median (IQR) 9 (5 to 16) 13 (8 to 19) 12 (8 to 16) 10 (5 to 15) 8 (5 to 14) 6 (5 to 9) 14 (9 to 20) 13 (7 to 19) 10 (6 to 16) 
History of hypertension 255 (68%) 197 (58%) 42 (60%) 295 (68%) 277 (85%) 124 (71%) - 176 (68%) 1366/1977 (69%) 
History of diabetes mellitus 62 (17%) 51 (15%) 18 (26%) 92 (21%) 74 (23%) 34 (20%) - 62 (24%) 393/1976 (20%) 
History of previous ischaemic stroke 42 (11%) 29 (8%) 14 (20%) 68 (16%) 80 (25%) 22 (13%) - N/A 255/1720 (15) 
History of atrial fibrillation 82 (22%) 84 (25%) 30 (43%) 164 (38%) 128 (39%) 54 (38%) 40 (56) 126 (49%) 708 (35%) 
Systolic blood pressure on admission 
(mmHg) median (IQR) 
157 (140 to 170) 155 (141 to 170) 150 (135 to 164) 154 (138 to 170) 157 (140 to 172) 162 (140 to 178) 166 (140 to 190) 152 (140 to 166) 155 (140 to 170) 
Diastolic blood pressure on admission 
(mmHg) median (IQR) 
80 (70 to 90) 83 (73 to 93) 76 (64 to 86) 86 (77 to 96) 85 (74 to 95) 87 (74 to 100) - 83 (72 to 94) 
83 (74 to 94) 
*1959 
observations 
Any symptomatic ICH 28 (7%) 13 (4%) 7 (10%) 9 (2%) 10(3%) 6 (3%) 5 (7%) 6 (2%) 84 (4%) 
PH 65 (17%) 27 (8%) 13 (19%) 40 (9%) 24 (7%) - 7 (10%) 47 (18%) 223 (12%) 
PHr 20 (5%) 4 (1%) 0 (0%) 14 (3%) 8 (2%) 13 (7%) 2 (3%) - 58/1733 (3%) 
mRS median (IQR) 2 (1-4) 2 (1 to 4) 2.5 (1 to 4) 2 (1 to 4) 2 (1 to 4) 2 (1 to 3) 4 (3 to 6) 4 (1 to 5) 2 (1 to 4) 
mRS>2 at 3-6 months n (%) 169 (45%) 160 (47%) 35 (50%) 179 (41%) 158 (49%) 48 (30%) 24 (89%) 157 (65%) 930/1968 (47%) 
CMBs presence n (%) 80 (21%) 70 (21%) 11 (16%) 166 (38%) 80 (25%) 38 (22%) 14 (20%) 82 (32%) 541 (26%) 
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Single CMB, n (%) 46 (12%) 46 (14%) 8 (11%) 72 (17%) 52 (16%) 21 (12%) 6 (8%) 33 (13) 284 (14%) 
≥2 CMBs, n (%) 34 (9%) 24 (7%) 3 (4%) 94 (22%) 28 (9%) 17 (10%) 8 (11%) 49 (19) 257 (13%) 
2-4 CMBs, n (%) 22 (6%) 11 (3%) 2 (3%) 52 (12%) 19 (6%) 14 (8%) 6 (8%) 38 (15) 164 (8%) 
≥5 CMBs, n (%) 12 (3%) 13 (4%) 1 (1%) 42 (10%) 9 (3%) 3 (2%) 2 (3%) 11 (4) 93 (5%) 
5-10 CMBs, n (%) 9 (2%) 11 (3%) 1 (1%) 23 (5%) 5 (2%) 1 (1%) 0 (0%) 8 (3) 58 (3%) 
>10 CMBs, n (%) 3 (1%) 2 (1%) 0 (0%) 19 (4%) 4 (1%) 2 (1%) 2 (3%) 3 (1) 35 (2%) 
CAA-related CMBs 
(i.e. strictly lobar), n (%) 
31 (8%) 38 (11%) 0 (0%) 61 (14%) 41 (12%) 16 (9%) 1 (1%) - 188/1790 (11%) 
Non-CAA-related CMBs 
(i.e. mixed or strictly deep), n (%) 
49 (13%) 32 (9%) 11 (16%) 105 (24%) 39 (12%) 22 (13%) 13 (18%) - 271/1790 (15%) 
Categorical data presented as n (%). 
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Table 2. Risk of bias and quality indicators 
 = Yes; x = No; ? = not reported; CMB=cerebral microbleeds; ICH=intracerebral haemorrhage 
  
Study 
Study 
size 
(>100) 
Selection of 
exposed and 
non‐exposed 
cohorts from 
the same 
population 
CMB 
criteria 
clearly 
defined 
ICH 
criteria 
clearly 
defined 
Standardised 
rating scale or 
trained 
inter/intra-
observer 
agreement 
reported  
Classification 
of CMB 
distribution 
Assessments 
of CMB and 
ICH 
independent 
Adjusted 
results for 
other risk 
factors 
No. of quality 
indicators 
fulfilled 
Turc et al.                  8/8 
Kakuda et al. x         x     6/8 
Yan et al.                 8/8 
Dannenberg et al.                 8/8 
Gratz et al.             ?   7/8 
Moriya et al. x   x   x x ?   3/8 
Kimura et al.     x   x x     5/8 
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Table 3. Adjusted odds ratios (95% CI) for associations between cerebral microbleed (CMB) presence and burden and the risk of ICH after 
IV thrombolysis. Overall p-values for the main model including CMBs as a single categorical variable are shown in the right column for each 
outcome. Asterisks next to CMBs burden categories denote statistical significance  
 
Symptomatic ICH 
(per ECASS-2 definition) 
OR (95% CI); p-value 
(N=1973) 
Any HT (vs. no ICH) 
(per ECASS-2 definition) 
OR (95% CI); p-value 
(N=1806) 
PH (vs. no or non-PH ICH)† 
(per ECASS-2 definition) 
OR (95% CI); p-value 
(N=1806) 
PHr (remote parenchymal ICH, 
vs. no or non-remote ICH) 
OR (95% CI); p-value 
(N=1720) 
A. CMBs presence Model 1.42 (0.86-2.35) 0.94 (0.70-1.25) 1.50 (1.09-2.07) * 3.04 (1.73-5.35) *** 
B. Main Model (CMBs categorised according to burden) 
Single CMB 0.84 (0.39-1.82) 
Overall 
p=0.014 
0.98 (0.68-1.40) 
Overall 
p=0.239 
1.15 (0.75-1.79) 
Overall 
p=0.013 
1.75 (0.80-3.86) 
Overall 
p<0.00001 
2-4 CMBs 2.46 (1.26-4.80) * 1.13 (0.71-1.79) 1.60 (0.98-2.61) 3.99 (1.86-8.54) *** 
5-10 CMBs 0.47 (0.06-3.48) 0.85 (0.40-1.82) 2.06 (1.02-4.18) * 3.59 (1.16-11.19) * 
>10 CMBs 3.65 (1.17-11.42)* 0.13 (0.02-0.98)* 3.20 (1.40-7.29) * 
9.09 (3.25-25.40) 
*** 
C. Log CMBs number Model 1.36 (1.01-1.84)* 0.87 (0.70-1.08) 1.42 (1.17-1.74) ** 2.07 (1.57-2.74) *** 
 
All models are adjusted for the following co-variates: treatment delay (log transformed for normality), age, baseline stroke severity, MRI sequence (T2*-GRE vs. SWI) and 
field strength (1.5T vs. 3T) and stratified by centre. The ‘No CMBs’ group is the reference group for all analyses. 
*p<0.05; **p<0.005; ***p<0.001 †Results similar for PH vs. no ICH  
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Table 4. Adjusted odds ratios (95% CI) for cerebral microbleed (CMB) distribution and the risk of ICH after IV thrombolysis. Overall p-values 
for the Main model including CMBs as a single categorical variable are shown on the right column for each outcome. Asterisks next to CMBs 
burden categories denote statistical significance  
 
Symptomatic ICH 
(per ECASS-2 definition) 
OR (95% CI) 
PH (vs. no or non-PH ICH)† 
(per ECASS-2 definition) 
OR (95% CI) 
PHr (remote parenchymal 
ICH, vs. no or non-remote 
ICH) OR (95% CI) 
A. CAA-related CMBs Models  N=1458 N=1311 N=1458 
i. CAA-related CMBs presence Model 1.14 (0.49-2.67) 1.78 (1.05-3.00) * 3.26 (1.54-6.91) ** 
ii. Main Model (CAA-related CMBs categorised by burden) 
Single CMB 0.65 (0.19-1.19) 
Overall 
p=0.113 
1.42 (0.75-2.68) 
Overall 
p=0.06 
2.18 (0.85-5.61) 
Overall 
p=0.001 
2-4 CMBs 2.67 (0.74-9.66) 2.39 (0.91-6.27) 4.89 (1.51-15.82) * 
≥5 CMBs 2.31 (0.24-22.19) 4.77 (1.03-22.05) * 16.40 (2.87-93.58) ** 
iii. Log CMBs number Model 1.49 (0.74-2.98) 2.06 (1.32-3.21) ** 3.77 (2.12-6.71) *** 
B. Non-CAA-related CMBs Models 
N=1538 N=1386 N=1538 
i. Non-CAA-related CMBs presence Model 1.62 (0.89-2.96) 1.77 (1.55-2.70) * 2.99 (1.56-5.72) ** 
ii. Main Model (Non-CAA-related CMBs categorised by burden) 
Single CMB 1.20 (0.46-3.15) 
Overall 
p=0.123 
0.94 (0.45-1.97) 
Overall 
p=0.006 
1.35 (0.40-4.60) 
Overall 
p=0.003 
2-4 CMBs 2.79 (1.23-6.34)* 2.06 (1.06-4.01) * 3.62 (1.48-8.84) * 
5-10 CMBs 0.58 (0.08-4.38) 3.16 (1.45-6.86) ** 3.95 (1.24-12.56) * 
>10 CMBs 1.87 (0.41-8.51) 2.63 (0.99-7.01) 5.61 (1.71-18.36) ** 
iii. Log CMBs number Model 1.25 (0.88-1.76) 1.47 (1.16-1.87) ** 1.85 (1.37-2.50) *** 
 15 
All models are adjusted for the following co-variates: treatment delay (log transformed for normality), age, baseline stroke severity, MRI sequence (T2*-GRE vs. SWI) and 
field strength (1.5T vs. 3T) and stratified by centre. * Results similar for PH vs. no ICH. The ‘No CMBs’ group is the reference group for all analyses. 
*p<0.05; **p<0.005; ***p<0.001 
†Results similar for PH vs. no ICH 
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Table 5. Adjusted odds ratios (95% CI) for cerebral microbleeds (CMBs) and functional 
outcome after IV thrombolysis. 
 
Poor outcome (mRS>2) 
at 3-6 months 
OR (95% CI) (n=1894) 
Death at 3-6 months 
OR (95% CI) 
A. CMBs presence Model 1.26 (0.98-1.63) 0.86 (0.60-1.24) 
B. Main Model (CMBs categorised by burden) 
Single CMB 1.19 (0.86-1.64) 0.75 (0.45-1.21) 
2-4 CMBs 1.13 (0.76-1.70) 1.00 (0.56-1.78) 
5-10 CMBs 1.28 (0.69-2.39) 0.47 (0.16-1.39) 
>10 CMBs 3.99 (1.55-10.22)** 2.44 (0.92-6.49) 
C. Log CMBs number Model 1.28 (1.08-1.53)* 1.05 (0.82-1.34) 
CMBs distribution/presumed underlying aetiology 
CAA-related CMBs 
 
Log CMBs number Model 
≥5 CMBs Model † 
 
 
1.18 (0.81-1.75) 
4.18 (0.42-41.21) 
- 
Non-CAA-related CMBs 
 
Log CMBs number Model 
>10 CMBs Model 
 
 
1.30 (1.06-1.58)* 
3.39 (1.29-8.89)* 
- 
 
All models are adjusted for the following co-variates: treatment delay (log transformed for normality), age, 
baseline stroke severity, sex, hypertension, atrial fibrillation, MRI sequence (T2*-GRE vs. SWI and 1.5T vs. 3T). 
and stratified by centre. The ‘No CMBs’ group is the reference group for all analyses. 
*p<0.05; **p<0.005 
†Effect sizes not calculated for >10 CMBs due to the small number of patients. 
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